ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1102

Comorbidities and Causes of Hospitalizations in a Cohort of IgG4-Related Disease Patients from a Single Center
Abstract Number: 0577

Comorbidity Burden as Scored Using the Rheumatic Disease Comorbidity Index (RDCI) Is Associated with Varying Treatment Patterns in Patients with Inflammatory Arthritis – a Study Using the EHR-Derived Rheumatic and Arthritis Disease Information Registry (RADIR)
Abstract Number: 1346

Comparable Safety Profile of Guselkumab in Psoriatic Arthritis and Psoriasis: Results from Phase 3 Trials Through 1 Year
Abstract Number: 1654

Comparative Characteristics of the Natural Course of Early Rheumatoid Arthritis with Onset at a Young Age (18-49 Years) and Older (50 Years and Older) Patients Who Did Not Take DMARDs, Biologics, Other Targeted Drugs, Corticoids According to the Russian Register of Arthritis OREL
Abstract Number: 0938

Comparative Effectiveness and Treatment Survival of Different TNF Inhibitors for Axial Spondyloarthritis in Real-World Clinical Practice
Abstract Number: 0834

Comparative Effectiveness of TNF Inhibitor vs IL-6 Receptor Inhibitor as Monotherapy or Combination Therapy with Methotrexate in Patients with Rheumatoid Arthritis: Analysis from CorEvitas’ RA Registry
Abstract Number: L06

Comparative Safety of Gout “Treat-to-target” and “Usual Care” Treatment Strategies on Cardiovascular Outcomes Using Observational Data: Causal Inference Approach
Abstract Number: 1870

Comparative Study on Anti-TNF vs Tocilizumab for Treatment of Refractory Uveitic Cystoid Macular Edema Due to Behcet’s Disease: Multicenter Study of 49 Patients
Abstract Number: 0839

Comparative Treatment Effectiveness in Rheumatoid Arthritis with and Without Concomitant Sjögren’s Syndrome – Results from the Swiss Clinical Quality Management Cohort
Abstract Number: 1061

Comparing Consultation Patterns Across Telehealth Platforms and Face-to-Face Clinic in the Military Health System
Abstract Number: 1773

Comparing Efficacy of Guselkumab versus Ustekinumab in Patients with Psoriatic Arthritis: An Adjusted Comparison Using Individual Patient Data from DISCOVER 1&2 and PSUMMIT Trials
Abstract Number: 0135

Comparing Rheumatoid Arthritis (RA), Psoriatic Arthritis (PA) and Systemic Lupus Erythematosus (SLE) Total Cost of Care (TCC) in Those with Optimally Managed Depression to Those with Sub-optimally Managed Depression
Abstract Number: 1802

Comparison of Axial and Peripheral Manifestations in Patients with Psoriatic Arthritis and Ankylosing Spondylitis in Upadacitinib Clinical Trials
Abstract Number: 1761

Comparison of Belimumab and Standard of Care by Inverse Probability of Treatment Weighting Analyses Based on Propensity Score in Patients with Systemic Lupus Erythematosus in the Maintenance Phase
Abstract Number: 1817

Comparison of Composite Indices for Disease Activity in Patients with Psoriatic Arthritis Treated with Upadacitinib: A Post-Hoc Analysis from SELECT-PsA 1

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].